Related Experiment Video
Updated: May 22, 2026
08:07
Electromyometrial Imaging of Uterine Contractions in Pregnant Women
Published on: May 26, 2023
Myasthenia gravis in pregnancy: a case report
Sebastian Berlit1, Benjamin Tuschy, Saskia Spaich
1Department of Obstetrics and Gynecology, University Medical Center Mannheim, 68167 Mannheim, Germany.
Case Reports in Obstetrics and Gynecology
|May 9, 2012
Summary
Maternal myasthenia gravis (MG) during pregnancy poses significant risks, as illustrated by a case of a postpartum myasthenic crisis. Prompt interdisciplinary management is crucial for stabilizing high-risk pregnancies complicated by MG.
Area of Science:
- Obstetrics and Gynecology
- Neurology
- Immunology
Background:
- Myasthenia gravis (MG) is an autoimmune disorder affecting neuromuscular junctions.
- Pregnancy can influence the course of MG, posing risks to both mother and fetus.
- Early recognition and management are vital for adverse outcomes.
Observation:
- A 38-year-old parturient experienced a life-threatening myasthenic crisis postpartum following a cesarean section.
- The crisis involved respiratory insufficiency, generalized seizure, and cardiac-circulatory arrest.
- The newborn showed no signs of muscular weakness.
Findings:
- The case highlights the potential for severe, rapid deterioration in pregnancy-associated MG.
- Successful resuscitation and stabilization were achieved through intensive interdisciplinary care.
- Treatment included ventilatory support, pyridostigmine, azathioprine, and steroids.
Implications:
- Maternal MG in pregnancy is a high-risk condition requiring specialized obstetric and neurological care.
- Awareness of MG's potential impact on pregnancy is essential for obstetricians.
- Interdisciplinary collaboration is key for optimal diagnostic and therapeutic strategies in these complex cases.
Related Concept Videos
01:20Myasthenia Gravis: Overview and Treatment
Myasthenia gravis is a neuromuscular transmission disorder characterized by weakness and increased fatigability of skeletal muscles. It is an autoimmune disease affecting approximately one in 2000 people, where antibodies against the α1 subunit of nicotinic acetylcholine receptors are produced.
These antibodies interfere with the function of the nicotinic receptors in three ways: by binding to the receptor and disrupting acetylcholine binding; by causing cross-linking of receptors which leads...
These antibodies interfere with the function of the nicotinic receptors in three ways: by binding to the receptor and disrupting acetylcholine binding; by causing cross-linking of receptors which leads...
01:15Myasthenia Gravis: Diagnostic Tests
Myasthenia gravis is an autoimmune condition affecting neuromuscular transmission, causing generalized weakness in skeletal muscles. Initial diagnoses rely on patients' signs, symptoms, and medical history. The challenge lies in distinguishing myasthenia from other muscular dystrophies. An important diagnostic feature is the significant improvement of symptoms after administering anticholinesterase inhibitors.
The edrophonium test is a diagnostic tool for myasthenia gravis. It involves...
The edrophonium test is a diagnostic tool for myasthenia gravis. It involves...
01:22Myasthenia Gravis ll: Pathophysiology
The disease process of myasthenia gravis begins at the neuromuscular junction, where antibodies attack key proteins needed for muscle activation. This immune reaction weakens signal transmission, leading to the characteristic muscle fatigue and weakness that define the condition.Immune-Mediated DamageIn most individuals, antibodies target acetylcholine receptors (AChRs) on the postsynaptic membrane of muscle cells. By blocking acetylcholine binding, these antibodies prevent the nerve signal...
01:28Disorders of the Skeletal Muscle
The clinical conditions affecting the skeletal muscle tissue are broadly categorized as musculoskeletal and neuromuscular disorders.
Musculoskeletal disorders
Musculoskeletal disorders involve injuries and conditions affecting the skeletal muscles and associated connective tissues. These disorders can arise from acute biomechanical stresses or chronic overuse and can occur across different age groups. Common injuries include sprains, fractures, and muscular strains, often resulting from...
Musculoskeletal disorders
Musculoskeletal disorders involve injuries and conditions affecting the skeletal muscles and associated connective tissues. These disorders can arise from acute biomechanical stresses or chronic overuse and can occur across different age groups. Common injuries include sprains, fractures, and muscular strains, often resulting from...
01:26Chemical Synapses
Chemical synapses are specialized sites between two neurons or between a neuron and a non-neuronal cell like a muscle, glandular or sensory cell.
Because chemical synapses depend on the release of neurotransmitter molecules from synaptic vesicles to pass on their signal, there is an approximately one millisecond delay between when the axon potential reaches the presynaptic terminal and when the neurotransmitter leads to opening of postsynaptic ion channels. Additionally, this signaling is...
Because chemical synapses depend on the release of neurotransmitter molecules from synaptic vesicles to pass on their signal, there is an approximately one millisecond delay between when the axon potential reaches the presynaptic terminal and when the neurotransmitter leads to opening of postsynaptic ion channels. Additionally, this signaling is...
01:26Chemical Synapses
Chemical synapses are specialized sites between two neurons or between a neuron and a non-neuronal cell like a muscle, glandular or sensory cell.
Because chemical synapses depend on the release of neurotransmitter molecules from synaptic vesicles to pass on their signal, there is an approximately one millisecond delay between when the axon potential reaches the presynaptic terminal and when the neurotransmitter leads to opening of postsynaptic ion channels. Additionally, this signaling is...
Because chemical synapses depend on the release of neurotransmitter molecules from synaptic vesicles to pass on their signal, there is an approximately one millisecond delay between when the axon potential reaches the presynaptic terminal and when the neurotransmitter leads to opening of postsynaptic ion channels. Additionally, this signaling is...